MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-07-2023
Eargo EPS Ratio 2011-2025 | EAR
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.7 | -81.1 | -76.1 | -173 | -150 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -39.7 | -173 | -104 |
Quarterly EPS Ratio Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.83 | -1.21 | -1.06 | - | -25.7 | -16.5 | -15.6 | - | -2.02 | -0.5 | -0.36 | - | -57.7 | -23.7 | -43.8 | - | -46.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.36 | -57.7 | -18.1 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
5 | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-2.81 | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
-0.54 | $ 3.84 | -0.65 % | $ 133 M | USA |
 |
Bio-Rad Laboratories
BIO
|
-25.6 | $ 304.89 | -1.05 % | $ 8.6 B | USA |
 |
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
-0.75 | - | 37.08 % | $ 85.7 M | USA |
 |
InMode Ltd.
INMD
|
2.29 | $ 14.38 | -0.9 % | $ 1.14 B |  Israel |
 |
IRIDEX Corporation
IRIX
|
-0.59 | $ 0.96 | 4.68 % | $ 15.5 M | USA |
 |
IRadimed Corporation
IRMD
|
1.52 | $ 96.85 | 0.64 % | $ 1.23 B | USA |
 |
Bruker Corporation
BRKR
|
0.76 | $ 45.3 | 0.38 % | $ 6.75 K | USA |
 |
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
7.67 | $ 128.53 | 2.45 % | $ 224 B | USA |
 |
Boston Scientific Corporation
BSX
|
1.26 | $ 91.99 | -0.64 % | $ 135 B | USA |
 |
Conformis
CFMS
|
-6.99 | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
1.17 | $ 62.62 | -0.21 % | $ 3.4 B |  Britain |
 |
LENSAR
LNSR
|
-2.73 | $ 11.61 | 0.87 % | $ 134 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-0.51 | $ 3.11 | 7.99 % | $ 116 M |  France |
 |
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-2.87 | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | USA |
 |
PAVmed
PAVM
|
-9.16 | $ 0.32 | -3.88 % | $ 2.31 M | USA |
|
Cognyte Software Ltd.
CGNT
|
-0.17 | $ 9.66 | -2.03 % | $ 694 M | Israel |
 |
Profound Medical Corp.
PROF
|
1.5 | $ 7.62 | 4.08 % | $ 180 M |  Canada |
 |
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | USA |
 |
Quanterix Corporation
QTRX
|
-0.86 | $ 7.45 | -1.46 % | $ 280 M | USA |
 |
Align Technology
ALGN
|
5.63 | $ 163.97 | -0.89 % | $ 12.3 B | USA |
 |
Accuray Incorporated
ARAY
|
-0.02 | $ 1.06 | - | $ 109 M | USA |
 |
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-0.7 | $ 12.55 | -1.26 % | $ 339 M | USA |
 |
FONAR Corporation
FONR
|
1.78 | $ 14.81 | 0.41 % | $ 97.1 M | USA |
 |
AxoGen
AXGN
|
-0.23 | $ 29.79 | -1.96 % | $ 1.32 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
4.29 | $ 39.86 | -2.38 % | $ 1.23 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-1.64 | $ 17.71 | 0.62 % | $ 409 M | USA |
 |
Globus Medical
GMED
|
0.76 | $ 86.17 | -0.61 % | $ 11.7 B | USA |
 |
Sensus Healthcare
SRTS
|
0.41 | $ 3.67 | -4.18 % | $ 59.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-0.09 | $ 13.54 | 0.86 % | $ 1.04 B | USA |